Cardeza Foundation for Hematologic Research, Department of Medicine, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA.
Cyrus Tang Hematology Center, Soochow University, Suzhou, China.
Blood Adv. 2022 Aug 9;6(15):4524-4536. doi: 10.1182/bloodadvances.2022007007.
The critical role of G protein-coupled receptor kinase 2 (GRK2) in regulating cardiac function has been well documented for >3 decades. Targeting GRK2 has therefore been extensively studied as a novel approach to treating cardiovascular disease. However, little is known about its role in hemostasis and thrombosis. We provide here the first evidence that GRK2 limits platelet activation and regulates the hemostatic response to injury. Deletion of GRK2 in mouse platelets causes increased platelet accumulation after laser-induced injury in the cremaster muscle arterioles, shortens tail bleeding time, and enhances thrombosis in adenosine 5'-diphosphate (ADP)-induced pulmonary thromboembolism and in FeCl3-induced carotid injury. GRK2-/- platelets have increased integrin activation, P-selectin exposure, and platelet aggregation in response to ADP stimulation. Furthermore, GRK2-/- platelets retain the ability to aggregate in response to ADP restimulation, indicating that GRK2 contributes to ADP receptor desensitization. Underlying these changes in GRK2-/- platelets is an increase in Ca2+ mobilization, RAS-related protein 1 activation, and Akt phosphorylation stimulated by ADP, as well as an attenuated rise of cyclic adenosine monophosphate levels in response to ADP in the presence of prostaglandin I2. P2Y12 antagonist treatment eliminates the phenotypic difference in platelet accumulation between wild-type and GRK2-/- mice at the site of injury. Pharmacologic inhibition of GRK2 activity in human platelets increases platelet activation in response to ADP. Finally, we show that GRK2 binds to endogenous Gβγ subunits during platelet activation. Collectively, these results show that GRK2 regulates ADP signaling via P2Y1 and P2Y12, interacts with Gβγ, and functions as a signaling hub in platelets for modulating the hemostatic response to injury.
G 蛋白偶联受体激酶 2(GRK2)在调节心脏功能方面的关键作用已被研究超过 30 年。因此,靶向 GRK2 已被广泛研究作为治疗心血管疾病的新方法。然而,其在止血和血栓形成中的作用知之甚少。我们在这里提供了第一个证据,表明 GRK2 限制血小板激活并调节损伤后的止血反应。在 CRE 肌肉小动脉中激光诱导损伤后,GRK2 缺失的小鼠血小板引起血小板聚集增加,尾巴出血时间缩短,并增强了腺苷 5'-二磷酸(ADP)诱导的肺血栓栓塞和 FeCl3 诱导的颈动脉损伤中的血栓形成。GRK2-/-血小板在 ADP 刺激下表现出整合素激活、P-选择素暴露和血小板聚集增加。此外,GRK2-/-血小板在 ADP 再刺激下仍具有聚集能力,表明 GRK2 有助于 ADP 受体脱敏。GRK2-/-血小板中这些变化的基础是 ADP 刺激下 Ca2+动员、RAS 相关蛋白 1 激活和 Akt 磷酸化增加,以及 ADP 存在时环腺苷酸水平升高减弱。在损伤部位,P2Y12 拮抗剂治疗消除了野生型和 GRK2-/- 小鼠血小板聚集之间的表型差异。人血小板中 GRK2 活性的药理学抑制增加了对 ADP 的血小板激活。最后,我们表明 GRK2 在血小板激活过程中与内源性 Gβγ 亚基结合。总的来说,这些结果表明 GRK2 通过 P2Y1 和 P2Y12 调节 ADP 信号转导,与 Gβγ 相互作用,并作为血小板中调节损伤后止血反应的信号枢纽。